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Background: Elevated IL-6 levels have been associated with advanced stage of breast cancer and
metastasis-related morbidity. The present prospective study was carried out to assess the effect of
neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma
breast.
Materials: All locally advanced carcinoma breast cases presenting to the surgery out patient’s department
were included in the study excluding pregnant or lactating females and those patients who were unﬁt for
anthracycline based chemotherapy. A total of 30 cases were included. The various parameters that were
evaluated include detailed clinico-pathological proﬁle and IL-6 levels. Clinical staging using TNM clas-
siﬁcation was performed in all enrolled patients. This included documenting tumor size (on USG), node
status and metastatic workup. First blood sample was collected before start of any treatment. Second
blood sample was collected after 3 cycles of chemotherapy. Blood was centrifuged within 30 min and
serum kept at 80 C until analysis for IL-6. IL-6 levels were quantiﬁed by ELISA.
Results: Majority of patients presented in stage T3N1M0 (66.66%). The serum level of IL-6 increased as the
disease progressed from T3N1M0 to T4dN2M0 (41.4  31.9 pg/ml vs. 164.0  31.1 pg/ml respectively).
A progressive reduction in IL-6 levels with subsequent cycles of chemotherapy was observed which was
statistically signiﬁcant (from72.856.0pg/ml to47.061.9pg/ml;pvalue0.002wilcoxan signed rank test).
Conclusion: Our study shows a consistent decline in the IL-6 levels with chemotherapy. Upon ratiﬁcation
of our ﬁndings by large population based multi centric studies, we may state with conviction that a single
blood test as serum level of IL6 will prove beneﬁcial in assessing the efﬁcacy of chemotherapy.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A wide repertoire of cytokines is secreted by the breast tumors
with IL-6 being one of them.1 The involvement of IL-6 at the cellular
level is reﬂected by the results of serum studies of cancer patients,
where IL-6 has been proven to be a valuable indicator of prognosis
and tumor load. Elevated IL-6 levels have been associated with
advanced stage of the disease and metastasis-related morbidity.
There are studies showing rise in IL-6 levels with increasing tumor
size, lymph node involvement, adipose tissue invasion and distant
metastasis.2e4 It can now be fathomed that high IL-6 serum levels
provide an environment that is favorable to tumor growth.5Gupta), binita.dr@gmail.com
ciates Ltd. Published by Elsevier LtNeoadjuvant chemotherapy is often used preoperatively to
decrease the tumor load in patients of locally advanced carcinoma
breast. Since serum IL-6 levels are directly correlated to tumor load,
it is expected that there should be a fall in these levels with
decreasing tumor load. The present prospective study was carried
out to assess the effect of neoadjuvant chemotherapy on circulating
levels of serum IL-6 in patients of locally advanced carcinoma
breast.2. Materials and methods
A prospective study was conducted in the Department of Surgery in collabora-
tion with Department of Biochemistry, Maulana Azad Medical College and associ-
ated Lok Nayak Hospital and G B Pant Hospitals, New Delhi from May 2010 to April
2011. All locally advanced carcinoma breast cases presenting to the surgery out
patient’s department were included in the study excluding pregnant or lactating
females and those patients who were unﬁt for anthracycline based chemotherapy. Ad. All rights reserved.
Fig. 2. Distribution of IL-6 levels according to stage of the disease.
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patient consent and clearance by the institutional ethical committee.
The various parameters that were evaluated include detailed clinico-
pathological proﬁle and IL-6 levels. Clinical staging using TNM classiﬁcation was
performed in all enrolled patients. This included documenting tumor size (on USG),
node status andmetastatic workup. The American Joint Committee on Cancer (AJCC)
TNM staging system was used for staging of the patients.
First blood sample was collected before start of any treatment. 5 ml of blood was
drawn from the antecubital vein of the patient after applying tourniquet to armwith
24 gauge needle in the morning. Venous blood was collected in a plain vial. After
enrollment into the study, each patient received 3 cycles of neoadjuvant chemo-
therapy (Cyclophosphamide, adriamycin and 5-ﬂuorouracil based) at 3 weekly
interval. Second blood sample was collected after 3 cycles of chemotherapy. Blood
was centrifuged within 30 min and serum kept at 80 C until analysis for IL-6. IL-6
levels were quantiﬁed by ELISA.
2.1. Assessment of response to chemotherapy
Ultrasound examination of the breast mass was performed using high frequency
5e12 MHz transducer. Response to chemotherapy was assessed by measuring the
size of mass on serial ultrasound, before and after each cycle of chemotherapy.
Clinical response was categorized by using the classiﬁcation system of the World
Health Organization (WHO). The two largest perpendicular diameters of the primary
tumor were measured and their product was calculated. Patients were categorized
as being in complete remission if there was no clinical evidence of tumor remaining
in the breast. A partial response was deﬁned as a reduction in the diameter product
of more than 50%. If there was an increase of 25% in the diameter product, the
patient was considered to have progressive disease. Patient whose tumor response
did not meet the deﬁnitions of complete remission, partial response or progressive
disease, were considered to have stable disease.
All patients underwent modiﬁed radical mastectomy after neoadjuvant
chemotherapy. Tissue specimens were examined for evidence of invasion, tumor
size, mitotic index, histologic grade, receptor status, axillary lymph node status and
adipose tissue invasion.
2.2. Statistical analysis
The data was analyzed by using SPPS statistical software version 16.0. Wilcoxan
signed rank test was used to determine the statistical signiﬁcance on different points
of time within the same group.
3. Results
Age of patients varied from 32 to 66 years. Themean age in years
was 47.7yrs. Stage distribution of patients is depicted in Fig. 1.
Majority of patients presented in stage T3N1M0 (66.66%). The 43.3%
(n ¼ 13) patients were of premenopausal age group and 56.6%
(n ¼ 17) patients were of postmenopausal age group.
The serum level of IL-6 increased as the disease progressed from
T3N1M0 to T4dN2M0 (41.4  31.9 pg/ml vs. 164.0  31.1 pg/ml
respectively) (Fig. 2).
Overall mean value of baseline serum IL-6 in this study was
72.8  56.0 pg/ml. After 3 cycles of chemotherapy this value came
down to 47.0  61.9 pg/ml.Fig. 1. Stage-wise distribution.The reduction in IL-6 values after 3 cycles of chemotherapy were
signiﬁcant for IL-6 (p value 0.002 wilcoxan signed rank test) as
summarized in Table 1.
The fall in IL-6 levels with neoadjuvant chemotherapy were
signiﬁcant for both T3 and T4 tumors. In T3 tumors, levels dropped
from41.4 31.9 to 29.6 pg/mlwhereas in T4 tumors, levels changed
from 135.5  37.5 to 72.5  56.03 pg/ml (p < 0.05).
Partial or complete response to chemotherapy was seen in 19
patients whereas disease was stable or progressive in 11 patients.
Those who responded well to chemotherapy also showed a signif-
icant decline in IL-6 levels (from 55.2  44.1 to 14.3  12.9 pg/ml;
p< 0.05). In patients having stable or progressive disease, therewas
no signiﬁcant fall in IL-6 levels (from 107.6  59 to 104.5  71.3 pg/
ml) (Table 2).
There was a statistically signiﬁcant correlation of IL-6 levels
with advancing axillary lymph node involvement, histologic grade,
adipose tissue invasion and mitotic index. The levels were
102.0  68.3 and 55.8  40.5 pg/ml in tumors with mitotic index 2
and 1 respectively.4. Discussion
Efﬁcacy of neoadjuvant chemotherapy in the management of
breast cancer in particular, is beyond doubt in locally advanced
breast cancer; primarily due to its ability to downsize large
tumors.6 Several randomized prospective studies on breast cancer
patients have proved the safety and efﬁcacy of neoadjuvant
chemotherapy.
Cytokines regulate function of many cells in an additive,
synergistic or antagonistic manner. Interleukin-6 (IL-6) is mainly
secreted by ﬁbroblasts, macrophages and lymphocytes (mainly TH2
cells). It is a multi-poietic cytokine that promotes the growth and
differentiation of immune cells, the production of other cytokines,
and acute-phase protein synthesis. It promotes tumor growth by
up-regulating antiapoptotic and angiogenic proteins in tumor
cells.7e9 IL-6 is associated with angiogenesis by virtue of its ability
to induce the mRNA of vascular endothelial growth factor (VEGF),Table 1
Baseline and post chemotherapy levels of IL-6.
Baseline Post chemotherapy
(3 cycles)
p valuea
IL-6 (pg/ml) 72.7  56.0 47.0  61.9 0.002
Bold value represents p < 0.05.
a Wilcoxan signed rank test.
Table 2
Changes in IL-6 levels according to clinical response.
Partial/complete
response
Stable/progressive
disease
Number of patients 19 11
IL-6 (Pre chemotherapy)
(pg/ml)
55.2  44.1 107.6  59
IL-6 (Post chemotherapy)
(pg/ml)
14.3  12.9 104.5  71.3
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have been shown to be signiﬁcantly more in patients with breast
cancer as compared to normal healthy women, which was corre-
lated with clinical stage of disease and poor survival.2e4 Production
of IL6 is up-regulated by cytokines such as TNF and IL-1, as well as
by certain oncogenes.11
In our previous study, we found a direct correlation of serum IL-
6 levels with stage, lymph node metastasis and adipose tissue
invasion.2 This study was carried out to ﬁnd out the effect of
anthracycline based chemotherapy on these levels; fall in which
will further strengthen the correlation of IL-6 levels with tumor
load. No such study has been carried out on Indian patients to the
best of our knowledge.
Very few studies are available in literature that has evaluated
the effect of CAF regimen on IL-6 levels. We found signiﬁcant
decrease in serum levels of IL-6 after the patients received 3 cycles
of chemotherapy concordant with a similar study done by Yokoe
et.al.12 On the contrary, Chala et al., found no effect of chemo-
therapy on these levels in a small subset of 10 patients (stage 4).13
Another study by Tsavaris et al., evaluated the effect of taxane
therapy on cytokine levels. They reported a rise in IL-6 levels with
progression of chemotherapy. This may be attributed to the
immunomodulatory effect of taxanes on the T cells.14
There are a few limitations of our study. Firstly, the small sample
size is a major impediment. A larger sample size with appropriate
representation of each stage would have been preferable for better
interpretation of our data. Secondly, a long term follow up would
have enabled us to correlate the IL6 levels with recurrence and 5
year survival rates. These could not be achieved due to managerial
and ﬁnancial constraints.
5. Conclusion
Cytokines have been proven to be mediators in the entire
spectrum of carcinogenesis since the initiation to ﬁnal metastatic
spread. Our study shows a consistent decline in the IL-6 levels with
chemotherapy. Upon ratiﬁcation of our ﬁndings by large population
based multi centric studies, we may state with conviction that
a single blood test as serum level of IL6 will prove beneﬁcial in
assessing the efﬁcacy of chemotherapy.Ethical approval
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